Skip to main content
INNOVA CAPTAB LIMITED logo

INNOVA CAPTAB LIMITED — Investor Relations & Filings

Ticker · INNOVACAP ISIN · INE0DUT01020 LEI · 549300SNL5HFUHE66804 BSE.NS Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2024-11-08 Regulatory Filings
Country IN India
Listing BSE.NS INNOVACAP

About INNOVA CAPTAB LIMITED

https://www.innovacaptab.com

Innova Captab Limited is an integrated pharmaceutical company focused on the research, development, manufacturing, and marketing of a wide range of pharmaceutical formulations. The company operates primarily as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive services to leading domestic and international pharmaceutical brands. Its product portfolio includes diverse dosage forms such as tablets, capsules, dry syrups, ointments, and injections across multiple therapeutic areas, including anti-infectives, analgesics, and gastrointestinal treatments. Innova Captab maintains a strong emphasis on R&D and quality control, operating advanced manufacturing facilities that adhere to global regulatory standards. In addition to its CDMO business, the company manages a domestic branded generics division and an international export business, catering to a global clientele with a focus on high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) dated November 8, 2024, informing about the approval of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024. It mentions the submission of a newspaper advertisement extract pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document does not contain the actual financial results or detailed financial statements but rather an announcement of the publication of these results in newspapers. The length is about 15,000 characters, but the content is primarily an announcement and submission of a newspaper extract, not the full financial report itself. Therefore, according to the MENU VS MEAL RULE, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the publication of financial results, not the results themselves.
2024-11-08 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a formal statement addressed to stock exchanges regarding the deviation or variation in the utilization of funds raised through an Initial Public Offer (IPO). It references Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides a detailed table showing no deviation in fund usage for the quarter and half year ended September 30, 2024. The document is a compliance disclosure about fund utilization and does not contain financial statements or detailed financial performance data. It is not an annual or interim report, earnings release, or audit report. It is also not a report publication announcement since it contains substantive content rather than just a notice. The document fits best under Regulatory Filings (RNS) as it is a regulatory compliance disclosure that does not fit other specific categories.
2024-11-07 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is an investor presentation dated November 7, 2024, for the quarter and half year ended September 30, 2024. It includes detailed financial performance highlights such as revenue, EBITDA, PAT, and balance sheet data for Q2 FY25 and H1 FY25. The text explicitly states it is an "Investor Presentation" and is intended for an earnings call with analysts and investors. The content includes forward-looking statements, company overview, strategic initiatives, and detailed financial metrics, which are typical of investor presentations. There is no indication that this is a full annual report, audit report, or regulatory filing. The document is not a brief factsheet or a simple announcement but a detailed presentation for investors. Therefore, the appropriate classification is Investor Presentation (IP).
2024-11-07 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated November 7, 2024, announcing the unaudited financial results for the quarter and half year ended September 30, 2024. It contains key financial highlights such as revenue, EBITDA, and profit after tax for Q2 FY25 and H1 FY25, along with management commentary. The document is not a full financial report but an initial announcement of quarterly/periodical financial results. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). It is also not a full Annual Report (10-K) or any other detailed filing. The document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. H1 2025
2024-11-07 English
Financial Result Updates
Regulatory Filings
2024-11-07 English
Outcome of Board Meeting
Regulatory Filings
2024-11-07 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.